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Lichen planus (LP) is a common inflammatory disease of the 
skin and mucosa, which also involves the oral epithelium. 
First introduced in 1869, this disease affects approximately 
0.5–1% of the world’s population; out of which, 50% develop 
cutaneous and 25% only manifest oral mucosal lesions.1,2 
Cutaneous LP may manifest in the form of a small wound 
(usually 2 cm in diameter), which may even reach 3 cm in 
diameter. Cutaneous LP lesions are often itchy and may man- 
ifest as white to purple bilateral papules.3 
Oral LP (OLP) is a chronic condition that may last for 
years and can be accompanied by genital mucosal or cuta- 
neous lesions. OLP may occur in all parts of the oral cavity; 
however, it most commonly involves the buccal mucosa, the 
tongue and gingiva. These lesions often appear bilaterally 
and symmetrically in different forms such as papules, ero- 
sive plaque, reticular lesion, atrophic lesion or bullous lesion. 
Clinically, the reticular, papule and plaque types are painless 
white keratotic lesions; whereas, erosive, atrophic and 
bullous lesions cause burning sensation in the mouth and are 
associated with moderate to severe pain.4-6 Although no 
definite etiology has been found for LP, most researchers 
believe that it is an inflammatory autoimmune  disease.7 
The World Health Organization classifies OLP as a poten- 
tially malignant condition; although the risk of malignancy of 
oral LP is lower than that of leukoplakia and erythroplakia. 
Risk of malignant transformation of OLP to oral squamous 
cell carcinoma (OSCC) is 0.4 to 5% in a mean period of four 
years; thus, it can be stated that LP is a preneoplastic lesion.8 
 
Pre-neoplastic lesions are those with a higher risk of 
transformation to neoplasms than the healthy tissues.9 Micro- 
scopically, these lesions show variable degrees of specific 
microscopical changes referred to as dysplasia.10 Oral epithe- 
lial dysplastic lesions may show different phenotypes of 
different stages of progression ranging from a normal healthy 
tissue to a neoplastic lesion. This malignant transformation 
can be categorized into three groups of mild, moderate and 
severe based on the degree of abnormality of the cells and 
thickness of dysplastic layers compared to healthy tissue. Assess- 
ment of the degree of malignancy can serve as a predictor of 
disease condition and prognosis.11 
Expression of several markers in OLP can increase the risk 
of its malignant transformation to OSCC; out of which, 
ALDH1, P53, BCL2, BAX, CD133, E-cadherin and PCNA can 
be named.12-15 Expression of COX2 and MMP is high in OSCC; 
moreover, these factors are rarely expressed in healthy mucosal 
tissue, moderately in LP and highly in OSCC; thus, their 
expression is an indicator of higher potential for malignancy.16 
Considering the fact that dysplastic changes occur in many 
cases of OLP and its malignant transformation to OSCC has 
been frequently reported, it is particularly important to be 
able to predict its malignant transformation to OSCC as in 
leukoplakia and other preneoplastic lesions. Several studies 
have assessed the expression of E-cadherin in OSCC and also 
in different types of leukoplakia with variable degrees of epi- 
thelial dysplasia. However, studies on the expression of this 
marker in oral LP with and without dysplasia and those trans- 
formed to OSCC are scarce. Thus, this study sought to assess 
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the expression of E-cadherin in different types of OLP to find 
out whether this marker can be used to predict the risk of 
malignant transformation to OSCC. 
 
Methods 
This descriptive cross-sectional study was conducted on 
patient records and formalin-fixed, paraffin-embedded tissue 
blocks retrieved from the archives of the Department of 
Pathology, School of Dentistry, Shahid Beheshti University of 
Medical Sciences, from 2004 to 2014 with definite diagnosis 
of OLP whose diagnoses were confirmed by the pathologist of 
our team. This study was approved in the ethics committee of our 
university (code:157). Sampling was census. All tissue sam- 
ples including 111 slides with definite diagnosis of OLP were 
retrieved; out of which, 67 were excluded due to tissue inade- 
quacy. Thus, 44 specimens with adequate tissue remained in 
the study. A questionnaire asking for the age and sex of each 
patient, site of lesion and its microscopic diagnosis was filled 
out for each case based on the data extracted from patient 
records. The respective slides were retrieved and evaluated by 
a pathologist to confirm the primary diagnosis and assess the 
presence/absence of dysplasia. The sections were deparaffin- 
ized with xylene and rehydrated in graded ethanol, then to 
block endogenous peroxidase activity they were incubated in 
0.3% hydrogen peroxidase in methanol for 30 minutes at 
room temperature. For antigen retrieval, specimens were 
incubatedwithretrieval solution(Tris 1/21; code 8382E510221 
+ EDTA 0.37 g; Merck, Darmstadt, Germany) with a PH of 6 
for 15 minutes in a microwave. Then, the tissue specimens 
were incubated with primary antibodies at room temperature 
for one hour. For this purpose, E-cadherin monoclonal mouse 
anti-human antibody (Clone NCH-38, code M3612; Dako, 
Glostrup, Denmark) was used. The indirect peroxidase system 
En Vision Kit (Dako Real Envision + system+ HRP Rabit/ 
Mouse K 3468) was used. To visualize the staining, the sec- 
tions were reacted by 3,3`-diaminobezidine (DAB, 
Code:K3468; Dako, Glostrup, Denmark). The specimens 
were subsequently counterstained with Mayer’s hematoxylin 
and mounted. Invasive ductal carcinoma of the breast was 
used as the positive control and the healthy adjacent epithe- 
lium was used as the internal positive control. For the nega- 
tive control, staining was done in absence of primary antibody 
and TBS was used instead of it. 
Staining was considered positive when the cell membrane 
and cytoplasm of the epithelial cells showed abnormal staining. 
Expression of E-cadherin was assessed using the following two 
scales: The intensity score (IS) for staining quality and the pro- 
portional score (PS) or the percentage of stained cells. The total 
score (TS) was defined as the sum of IS and PS. Number of 
stained cells in the superficial and deep layers was determined 
under a light microscope. Based on the percentage of staining, 
four categories were defined for stained cells in the superficial 
layer as follows: Score 0: <50%, score 1: 50%–69%, score 2: 










Fig 1. E-cadherin expression in superficial and deep layers of 
epithelial tissue of OLP. (A) High expression in superficial and 
low expression in deep layers of OLP without dysplasia. (B) No 
expression in superficial and deep layers of OLP with dysplasia. 
(A) x100, (B) x200. 
 
(IS) of the cells in the superficial layer, four categories were defined: 
Score 0: , score 1 = + (mild), score 2 = ++ (moderate), score 3: 
+++ (strong). Based on the number and percentage of stained 
cells in deep layers, four groups were defined: Score 0: < 30%, score 
1: 30% < PS < 90%, score 2: 100%. Based on the IS of cells in 
deep layers, two categories were defined: Score 0: No (negative) 
staining, score 1: positive staining. 
Statistical Analysis 
Data were analyzed using SPSS version 21 (SPSS Inc., IL, USA). 
The relationship between the immunoexpression of E-cadherin 
and presence of dysplasia in OLP was assessed by the Mann 
Whitney U test. Level of significance was set at P < 0.05. 
 
Results 
For intra-rater agreement, immunoexpression was evaluated 
two weeks later. For inter-rater agreement, another patholo- 
gist evaluated the specimens. Of all OLP specimens, dysplasia 
was present in 27.3% (n = 12) and absent in 72.7% (n = 32). Of 
OLP tissue specimens with dysplasia, 41.6% (n = 5) belonged 
to males and 58.3% (n = 7) belonged to females. Of OLP spec- 
imens without dysplasia, 31.3% (n = 10) belonged to males 
and 68.8% (n = 22) belonged to females. Fisher’s exact test 
showed no significant difference between the two groups with 
and without dysplasia in terms of gender (P = 0.72). The mean 
age of patients was 51.1 years (range 38 to 75 years) and 52.8 
years (range 31–75 years) in OLP with and without dysplasia 
groups, respectively. Independent t-test showed no significant 
difference in the mean age of patients between the two groups 
(P = 0.69). Table 1 shows the frequency distribution of speci- 
mens based on the location of lesions (Table 1). 
In OLP specimens with dysplasia, the severity of dysplasia 
was mild in 91.6% (n = 11), moderate in 8.3% (n = 1) and 
severe in 0% (n = 0)(Fig. 1). 
Table 2 shows the scores of staining of the superficial 
layer for E-cadherin. As seen in Table 2, score 2 of IS had the 
highest frequency (56.8%, n = 25); out of which, 18 (40.9%) 
were non-dysplastic while seven (15.9%) were dysplastic 
lesions. According to the Mann Whitney U test, the IS of the 
Table 1. Frequency distribution of specimens based on the location of lesions 
Type of lesion Buccal mucosa Gingiva Tongue Hard palate Floor of the mouth Total 
OLP with dysplasia 6(50%) 2(16%) 2(16%) 1(8.3%) 1(8.3%) 12(100%) 
OLP without dysplasia 22(68.8%) 6(18.7%) 4(12.5%) 0(0%) 0(0%) 32(100%) 
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Table 3. Frequency distribution of the PS and TS for E-cadherin 

























P = 0.73 
 0 0(0) 4(12.5) 4(9)  
PS 1 0(0) 2(6.2) 2(4.5) P = 0.35 
 2 12(100) 26(81.2) 38(86.3)  
 0 0(0) 4(12.5) 3(6.3)  
 1 0(0) 1(3.1) 1(2.2) P = 0.35 
TS 
2 0(0) 2(6.2) 2(6.3) 
 










superficial layer for E-cadherin was not significantly different 
between the two groups of with and without dysplasia (P = 0.76). 
Score 3 of PS had the highest frequency among both dys- 
plastic (58.3%, n = 7) and non-dysplastic (56.2%, n = 18) lesions. 
Based on the results of the Mann Whitney U test, the PS of 
the superficial layer for E-cadherin was not significantly dif- 
ferent between the two groups of with and without dysplasia 
(P = 0.96). Score 4 of TS had the highest frequency in dys- 
plastic (50%, n = 6) and non-dysplastic (37.5%, n = 12) 
lesions. According to the Mann Whitney U test, the TS of 
expression of E-cadherin in the superficial layer was not sig- 
nificantly different between the two groups of with and 
without dysplasia (P = 0.90). 
Table 3 shows the frequency distribution of three scores in 
the deep layers. The IS for E-cadherin in the deep layers was 
score 1 in 100% (n = 12) of specimens in the dysplastic and 
96.8% (n = 31) of specimens in the non-dysplastic group. The 
frequency of score 0 was 0% (n = 0) in the dysplastic and 3.1% 
(n = 1) in the non-dysplastic group. According to the Mann 
Whitney U test, the difference in this regard between the two 
groups was not significant (P = 0.73). Score 2 of PS had 100% 
frequency (n = 12) in dysplastic specimens. Score 2 also had 
the highest frequency (81.2%, n = 26) in the non-dysplastic 
group. According to the Mann Whitney U test, the PS of 
expression of E-cadherin in the deep layers was not signifi- 
cantly different between the two groups of with and without 
dysplasia (P = 0.35). Score 3 of TS was noted in 100% of dys- 
plastic specimens (n = 12) while 81.2% (n = 26) of non- 
dysplastic specimens showed score 3. According to the Mann 
Whitney U test, the TS of expression of E-cadherin in the deep 
layer was not significantly different between the two groups of 
with and without dysplasia (P = 0.35). 
Of 12 dysplastic OLP lesions, in four specimens (33.3%), 
50–69% of the cells were stained in the superficial layer. In one 
specimen (8.3%), 70–89% of superficial cells and in seven 
specimens, more than 90% of the superficial cells were stained. 
Of 32 non-dysplastic OLP specimens, in three (9.3%), less 
than 50% of the cells were stained in the superficial layer. In 
five (15.6%), 50–69% of the cells, in six (18.7%), 70–89% of the 
cells and in 18 (56.2%) more than 90% of the cells were stained. 
In all 12 dysplastic LP specimens, all the cells were stained 
in deep layers. 
Of 32 non-dysplastic specimens, in four (12.5%) less than 
30% of the cells were stained in deep layers; in two (4.5%), 
30–90% and in 26 (86.2%) 100% were stained. Based on the 
Mann Whitney U test, the expression of E-cadherin was not 
significantly different between the groups (P > 0.05). 
Also, a case of dysplastic OLP progressed to OSCC   was 
found; despite the reduction in expression of E-cadherin in 
OSCC, this reduction was not statistically significant (P > 0.05). 
 
Discussion 
Cell adhesion molecules are proteins located on the surface  
of cells, which are responsible for adhesion of cells to each 
other or to the extracellular matrix. These proteins are 
intramembranous receptors composed of intracellular, 
intramembranous and extracellular components. The extra- 
cellular component is responsible for adhesion to intracellular 
component, hemophilic binding, adhesion to extracellular 
matrix and heterophilic binding. Adhesion molecules are 
divided into two groups of calcium-dependent and non- 
calcium dependent. The calcium-dependent group includes 
three groups of cadherins, integrins and selectins. Non- 
calcium dependent group includes lymphocyte homing 
receptors and IgSF.17 Cadherins are part of cell surface glyco- 
proteins that play a critical role in cell adhesion and binding 
to calcium.1,2 Thus, this is referred to as calcium-dependent 
cell adhesion. At present, more than 16 cadherin molecules 
have been recognized. Different cadherins have similar 
structure and are named based on their tissue location. 
Difference in expression patterns of cadherins and   dynamic 
Table 2. Frequency distribution of E-cadherin scores in the 















 0 0(0) 1(3.1) 1(2.2)  
 1 4(33.3) 11(34.3) 15(34) P = 0.76 
IS 2 7(58.3) 18(56.2) 25(56.8)  
 3 1(8.3) 2(6.2) 3(6.8)  
 0 0(0) 3(9.3) 3(6.8)  
 1 4(33.3) 5(15.6) 9(20.4) P = 0.96 
 2 1(8.3) 6(18.7) 7(15.9)  
PS 3 7(58.3) 18(56.2) 25(56.8)  
 0 0(0) 1(3.1) 1(2.2)  
 1 0(0) 1(3.1) 1(2.2) P = 0.90 
 2 0(0) 2(6.2) 2(4.5)  
 3 3(25) 5(15.6) 8(18)  
TS 4 6(50) 12(37.5) 19(43.1)  
 5 3(25) 10(31.2) 13(29.5)  
 6 0(0) 1(3.1) 1(2.2)  
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changes during development are among the significant 
properties of this molecular group. Due to the importance of 
cellular attachment loss in progression of malignant lesions, 
these markers have been extensively studied.18 
E-cadherin is an intramembranous calcium-dependent 
glycoprotein found on the surface of most epithelial cells. This 
120KD glycoprotein, also known as uvomorulin, L-CAM, 
ARC-1 and cell-CAM, is expressed in all epithelial cells. Its 
gene is located at position 16 q 22.1. Cells expressing E-cad- 
herin attach to other cells expressing E-cadherin and do not 
adhere to cells expressing other types of cadherins.18-20 E-cad- 
herin is expressed in normal oral epithelium in the spinous 
layer and basal layer. This marker is mainly located in zonula 
adherens. Its extracellular component contains three domains, 
which are activated in presence of calcium. When interacted 
with E-cadherin on the surface of adjacent cells, a firm cell-cell 
attachment is formed. Its cytoplasmic tail is related to a group 
of intracellular anchor proteins known as catenins.18 Studies 
have shown that cadherins are important predictors of tissue 
morphology, growth and development and their expression is 
developmentally adjusted. Evidence shows that cell adhesion 
mediated by E-cadherin is required for accumulation of mes- 
enchymal cells and their migration towards the epithelium.18 
Assessment of an in vitro model of epithelial injury revealed 
that destruction of cell-cell attachment via the E-cadherin/cat- 
enin axis was associated with cell migration and epithelial 
regeneration.18 Cadherin/catenin axis plays an important role 
in molecular histology of the tumors and any significant 
change in expression or structure of these components results 
in a separation in the adherens junction, decreased tumor dif- 
ferentiation and formation of an aggressive phenotype. A sig- 
nificant association has been reported between decreased 
expression of E-cadherin and beta-catenin with oral epithelial 
dysplasia21 and between normal oral mucosa and OPL 
lesions;22 however, previous study showed no relationship 
between OLP and E-cadherin expression.23 In vitro studies 
have shown that decreased cell adhesion by E-cadherin is 
associated with invasion and poorly differentiated phenotype 
in several cell lines of human carcinomas.18,24 Expression of 
E-cadherin has been evaluated in many human malignancies 
such as adenoma of the pancreas, esophagus, gastric mucosa 
and colon in vivo. Also, decreased or no expression of E-cad- 
herin along with poorly differentiated phenotype and lymph 
node involvement in some cancers has been associated with 
tumor recurrence and higher morbidity and mortality.18 
Recently, EGFR-type I and catenin expression in kerati- 
nocytes infected with HPV E7 and E6 protein was evaluated. 
Immortality of normal human keratinocytes by E6 and E7 
changes the subcellular orientation of E-cadherin and catenin 
with a shift from cell membrane towards an intra-cytoplasmic 
position with no change in level of expression. Progression 
towards a more aggressive phenotype capable of invading the 
collagen is associated with down regulation of E-cadherin and 
increased expression of EGF-R. Based on a previous study, 
decreased membranous positioning and expression of the 
cytoplasmic E-cadherin are directly correlated with the degree 
of dysplasia seen in stratified squamous epithelium. Thus, as 
the no expression of E-cadherin is a late occurrence in cervical 
carcinoma, decreased or deranged expression of E-cadherin 
and its cellular positioning occur much sooner in the dys- 
plastic phase; this indicates the pivotal role of destruction of 
E-cadherin/catenin axis in the initiation and progression     of 
tumors.18 Also, level of expression of E-cadherin is correlated 
with the aggressive behavior and poor prognosis, and the 
lower the expression of E-cadherin, the more aggressive the 
cancer and the poorer the prognosis.17 
In the recent years, several biological markers have been 
used to obtain information regarding OSCC such as P53 pro- 
to-oncogene, cyclin D1, tyrosine kinase receptors for growth 
hormone, markers related to neovascularization, increased 
expression of metalloproteinases and changed expression of 
cadherins, which are all associated with poor prognosis.17 
Assessment of the role of E-cadherin in determining the prog- 
nosis and progression of OSCC revealed that decreased 
expression of E-cadherin was associated with poor differentia- 
tion of cells, aggressive nature of tumor and metastasis.18 
The current study immunohistochemically assessed the 
expression of E-cadherin in OLP specimens with and without 
dysplasia. Based on the results, score 3 and higher expression 
of E-cadherin occurred in the superficial layer of 88% of non- 
dysplastic specimens; whereas, 100% of dysplastic specimens 
showed score 3 expression of this marker. Overall, no signifi- 
cant difference was noted in the IS of E-cadherin expression 
between the two groups. However, decreased expression of 
E-cadherin in the lesion compared to the adjacent healthy 
tissue was noted. Although in samples with and without dys- 
plasia, the frequency of score 6 was not significantly different 
(0% versus 3.1%), since the number of specimens with and 
without dysplasia was 12 and 32, respectively, this lack of a 
significant difference may be attributed to the difference in 
number of specimens in the two groups. Also, in deep layers, 
81.3% of non-dysplastic specimens had score 3 expression 
while 100% of dysplastic samples showed score 3 expression. 
In deep layers, scores 4, 5 and 6 were not seen in any group. 
This means that in the deepest epithelial layers of OLP, expres- 
sion of E-cadherin does not exceed score 3 (moderate expres- 
sion). In the deepest layer, expression of E-cadherin was 
slightly higher in dysplastic specimens, but not significantly. 
In two studies conducted by Neppelberg et al,25,26 expression of 
E-cadherin was assessed in non-dysplastic and dysplastic LP 
specimens and OSCC. The afore-mentioned two studies were 
the only ones assessing the reduction in E-cadherin expression 
in LP specimens with and without dysplasia. They reported 
the reduction in expression of E-cadherin in LP specimens. 
However, their first study was a descriptive one and did not 
compare this reduction with the expression of this marker in 
other tissues. Instead, it assessed the reduction in expression of 
this marker in specimens that transformed to OSCC.25 In the 
second study by Neppelberg et al,26 decreased expression of 
E-cadherin in an active LP site was compared to that in the 
healthy adjacent tissue; however, it was also a descriptive study 
and no quantitative assessment was done. We immunohisto- 
chemically compared OLP with and without dysplasia. Search 
of the literature yielded no similar study for quantitative com- 
parison with the current one. Thus, we compared our results 
with those of studies on leukoplakia with/without dysplasia. In 
our study, dysplastic specimens showed higher expression of 
E-cadherin, but not significantly. This result was different 
from the results of Kyrodimou et al,27 in their study on dif- 
ferent types of dysplastic leukoplakia and OSCC. They showed 
a significant association between the decreased expression of 
E-cadherin and increased risk of malignant transformation of 
dysplastic specimens and their higher aggressiveness and 
transformation to neoplastic lesions. Also, they  qualitatively 
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showed decreased expression of E-cadherin in the superficial 
and deep layers. 
Von   Zeidler  et  al.11  indicated  a  significant  association 
between decreased expression of E-cadherin and increased risk 
of dysplasia in leukoplakia specimens; these results were dif- 
ferent from our findings. Also, Santos-García et al,28 immuno- 
histochemically assessed the expression of E-cadherin, laminin 
and collagen IV in leukoplakia lesions with mild and moderate 
dysplasia and OSCC and showed a significant association 
between 20% reduction in expression of E-cadherin in speci- 
mens with mild and moderate dysplasia and 90% reduction in 
expression of E-cadherin in OSCC.28 Ishida et al,29 immunohis- 
tochemically assessed beta-catenin in leukoplakia specimens 
with and without dysplasia and indicated a significant differ- 
ence in nuclear localization of beta-catenin in leukoplakia spec- 
imens with dysplasia compared to healthy tissues. 
Asokan et al.30 evaluated epigenetic changes of tumor sup- 
pressor genes including p15, p16, MGMT, hMLH and E-cadherin 
in leukoplakia lesions with and without dysplasia and OSCC and 
showed a direct association between inactivity of E-cadherin gene 
and increased risk of malignant transformation. They did not 
perform immunohistochemistry but reported an association 
between decreased expression of E-cadherin and increased risk of 
malignancy in dysplastic lesions. Their findings were in contrast 
to ours since we found no significant difference in the expression 
of E-cadherin in specimens with and without dysplasia. This sug- 
gests that in addition to decreased expression of E-cadherin, 
some other mechanisms are probably involved in initiation and 
malignant transformation of OLP especially in the dysplastic 
type. In our study, E-cadherin expression decreased in dysplastic 
lesions but not significantly, which may be due to small sample 
size of dysplastic lesions11 compared to those without dysplasia. 
Thus, future studies on a larger sample size are required to better 
elucidate this topic. Also, it is suggested to assess the expression of 
beta-catenin along with E-cadherin in further studies. 
 
Conclusion 
Based on the current results, no significant difference was found 
in the expression of E-cadherin between dysplastic and non- 
dysplastic OLP lesions. Also, 100% of dysplastic specimens 
indicated variable degrees of expression of E-cadherin. It may 
be concluded that presence of dysplasia in OLP does not follow 
the same molecular pattern as in other oral precancerous lesions 
such as leukoplakia and therefor it cannot be a direct predictor of 
the prognosis and malignant transformation of lesions to OSCC. 
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